GLMDのチャート
GLMDの企業情報
| symbol | GLMD |
|---|---|
| 会社名 | Galmed Pharmaceuticals Ltd. （ガルメド・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC) called aramchol. Its product candidate aramchol is a disease modifying treatment for fatty liver disorders including Non-Alcoholic Steato-hepatitis (NASH). The Company''s Aramchol is a conjugate of cholic acid and arachidic acid which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials. ガルメド・ファ―マシュ―ティカルズはイスラエルの臨床段階のバイオ医薬品会社。肝臓疾患やコレステロ―ル胆石のための一日一回経口療法の新治療薬の開発・商品化に従事。画期的医薬品(ファ―スト・イン・クラス)には、脂肪酸と胆汁酸を結合させた「aramchol」があり、非アルコ―ル脂肪性肝炎などの脂肪管疾患の応用治療となる製品候補を保有する。 Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.It is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and plan to initiate a first in human study by the first quarter of 2021. |
| 本社所在地 | 16 Tiomkin Street Tel Aviv 6578317 ISR |
| 代表者氏名 | Chaim Hurvitz チャイム・ハービッツ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +972 3-693-8448 |
| 設立年月日 | 41456 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | 17人 |
| url | www.galmedpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/glmd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -11.49600 |
| 終値（lastsale） | 12.32 |
| 時価総額（marketcap） | 257645129.28 |
| 時価総額 | 時価総額（百万ドル） 241.76590 |
| 売上高 | 売上高（百万ドル） 1.08500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 147.66090 |
| 当期純利益 | 当期純利益（百万ドル） -11.63600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Galmed Pharmaceuticals Ltd revenues remained flat at $538K. Net loss decreased 11% to $5.2M. Revenues reflect market conditions. Lower net loss reflects Research and development expenses decrease of 24% to $3.9M (expense) Financial expenses net increase of 29% to $143K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to -$0.34. |
GLMDのテクニカル分析
GLMDのニュース
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday''s Mid-Day Session 2023/01/04 18:17:01 Benzinga
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS ) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) climbed 162% to $0.4909 after the company announced it acquired Amerigen 7. Cryptyde, Inc. (NASDAQ: TYDE ) gained 108% to $0.4022. Geron Corporation (NASDAQ: GERN ) shares jumped 53.3% to $3.6800 after the company announced top-line results from the IMerge Phase 3 trial of imetelstat in lower risk MDS. The trial met the primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint. Shift Technologies, Inc. (NASDAQ: SFT ) rose 49% to $0.2350. Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) jumped 42.4% to $0.4132. The company earlier reported in 13G filing Sabby Volatility Warrant Master Fund held 11% stake in Neptune Wellness Solutions. Reunion Neuroscience Inc. (NASDAQ: REUN ) gained 27.8% to $1.33. Armata Pharmaceuticals, Inc. (NASDAQ: ARMP ) surged 25% to $ 1.3799.
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol 2023/01/04 13:00:00 Benzinga
Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using AI-assisted, digital pathology reading Highly statistically significant (p<0.0001) reduction in liver stiffness by Fibroscan Highly statistically significant (p<0.0001) reduction in biochemical markers of liver injury ALT and AST Highly statistically significant reductions in major fibrosis biomarkers: FIB-4 (p<0.0001), Pro-C3 (p<0.0001) and ELF (p= 0.0038) at week 24 Galmed is submitting all data to the FDA to initiate discussions on incorporating more sensitive histology reading methodologies as primary endpoints in NASH clinical studies and is actively looking for partnering opportunities to continue Aramchol''s clinical development. TEL AVIV, Israel , Jan. 4, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD ) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases reported today full results from the Open-Label Part of the ARMOR study corroborating effects of Aramchol across all efficacy parameters.
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday''s Mid-Day Session 2023/01/03 18:39:39 Benzinga
Gainers Horizon Global Corporation (NYSE: HZN ) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. Jasper Therapeutics, Inc. (NASDAQ: JSPR ) gained 257% to $1.70 after the company announced clinical data from a Phase I/II trial of briquilimab as a conditioning treatment in sickle cell disease and beta thalassemia. ReShape Lifesciences Inc. (NASDAQ: RSLS ) shares jumped 142.3% to $16.34. Reshape Lifesciences recently announced a 1-for-50 reverse stock split. Lucira Health, Inc. (NASDAQ: LHDX ) surged 68% to $0.1875 after the company announced it submitted an Emergency Use Authorization application to the FDA for OTC use of its COVID-19 & Flu test. Swvl Holdings Corp. (NASDAQ: SWVL ) shares gained 43% to $0.1958 after the company reported commencement of strategic review process. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) jumped 41% to $0.5678. Vivos Therapeutics recently posted a Q3 loss of $0.26 per share. EpicQuest Education Group International Limited (NASDAQ: EEIQ ) gained 40.1% to $3.0962.
Galmed Pharmaceuticals gets an extension from Nasdaq to regain compliance 2022/12/15 10:13:02 Seeking Alpha
Galmed Pharmaceuticals (GLMD) received a letter from The Nasdaq, notifying the company that it is eligible for an additional 180 calendar day period, or until June 12, 2023.This…
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq''s Minimum Bid Price Requirement 2022/12/14 22:00:00 PR Newswire
TEL AVIV, Israel, Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced today that on December 13, 2022, it received a letter from The Nasdaq Stock…
Maxim Group Downgrades Galmed Pharmaceuticals to Hold 2022/08/08 11:35:02 Investing.com
https://www.investing.com/news/pro/maxim-group-downgrades-galmed-pharmaceuticals-to-hold-432SI-2866585
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold 2022/08/08 09:25:04 Investing.com
https://www.investing.com/news/pro/canaccord-genuity-downgrades-galmed-pharmaceuticals-to-hold-432SI-2866300
Rope in stocks: Mustang Bio, Inc. (NASDAQ:MBIO 8.78%), Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD -9.52%) 2022/08/05 00:32:23 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Rope in stocks: Mustang Bio, Inc. (NASDAQ:MBIO 8.78%), Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD -9.52%) appeared first on Stocks Equity .
Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral 2022/08/04 16:57:02 Investing.com
https://www.investing.com/news/pro/cantor-fitzgerald-downgrades-galmed-pharmaceuticals-to-neutral-432SI-2863917
Galmed Pharmaceuticals: Q2 Earnings Insights 2022/08/04 14:00:30 Benzinga
Galmed Pharmaceuticals (NASDAQ: GLMD ) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Galmed Pharmaceuticals beat estimated earnings by 37.5%, reporting … Full story available on Benzinga.com
Galmed''s Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model 2022/07/07 14:18:42 Benzinga
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) announced results showing significant effects of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model. Treatment with Aramchol resulted in statistically significant improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone, the gold standard … Full story available on Benzinga.com
Trading - Short Interest in Galmed Pharmaceuticals Ltd. Decreases By 27.3% 2022/05/31 00:07:09 Business Mag
Galmed Pharmaceuticals Ltd. saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 23,200 shares, a drop of 27.3% from…
Galmed Pharmaceuticals shares fall after downgrade by Raymond James analyst 2022/05/18 15:05:31 Seeking Alpha
Galmed Pharmaceuticals (GLMD) shares fell 8.41% after Raymond James Analyst Steven Seedhouse downgraded the ratings of the biotechnology company to Market Perform from Outperform without…
Galmed Pharmaceuticals: Q1 Earnings Insights 2022/05/17 12:25:23 Benzinga
Galmed Pharmaceuticals (NASDAQ: GLMD ) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Galmed Pharmaceuticals beat estimated earnings by 25.0%, reporting … Full story available on Benzinga.com
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results 2022/05/17 12:00:00 PR Newswire
TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022….